40.39 (-%)
As of Aug 10, 2023
Source:
Chinook Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on discovering, developing and commercializing precision medicines for kidney diseases. Our pipeline is focused on rare, severe chronic kidney diseases with well-defined clinical pathways. Our lead clinical program is atrasentan, a potent and selective endothelin A receptor antagonist.
Country | United States |
Headquarters | seattle, washington |
Phone Number | 206-485-7051 |
Industry | manufacturing |
CEO | Eric L. Dobmeier |
Website | www.chinooktx.com |